This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

JACOB COLSKY, M.D.

AMA Arch Intern Med. 1954;93(5):796-801.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

PRIOR to the introduction of stilbamidine in the treatment of systemic blastomycotic infections, by Schoenbach and co-workers,* there had been no generally effective therapy for this disease, although administration of iodides in conjunction with desensitization has been reported to have been successfully used in the treatment of some cases.³ Elson's observation that certain diamidines exerted a fungistatic effect upon Blastomyces dermatitidis⁴ led to the clinical trial of stilbamidine in patients who had systemic blastomycotic infections. The therapeutic results obtained in the treatment of this disease were excellent. Subsequently, Snapper and co-workers treated patients with extensive blastomycotic infections with 2-hydroxystilbamidine with good results.

Stilbamidine is one of the aromatic diamidines which has been used effectively in the treatment of kala-azar. However, because of undesirable sequelae developing in patients treated with this drug, it has been replaced to a great extent by propamidine, a less effective agent in the . . . [Full Text PDF of this Article]

Author Affiliations
BROOKLYN

From the Medical Services of the Maimonides Hospital and the Department of Medicine, State University of New York College of Medicine at New York City.

Footnotes
Dr. R. C. Pogge, of The Wm. S. Merrell Company, generously supplied the 2-hydroxystilbamidine used in this study.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?